Silver Book

Silver Book Fact

One economic model predicts that if type 1 and type 2 diabetics had begun Captopril (a drug that controls blood pressure and delays the onset of kidney failure) treatment in 1995, the aggregate health care cost savings in 1999 would have been $189 million and in 2004 would have been $475 million-a present value cumulative cost savings of $2.4 billion for those 10 years.

Rodby R, Firth L, Lewis E. An Economic Analysis of Captopril in the Treatment of Diabetic Nephropathy. Diabetes Care. 1996; 19(10): 1051-61. http://care.diabetesjournals.org/cgi/content/abstract/19/10/1051

Reference

Title
An Economic Analysis of Captopril in the Treatment of Diabetic Nephropathy
Publication
Diabetes Care
Publication Date
1996
Authors
Rodby R, Firth L, Lewis E
Volume & Issue
Volume 19, Issue 10
Pages
1051-61
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Improvements in key clinical measures over an average of 14.8 months in a community pharmacy health management program called the Diabetes Ten City Challenge, in which 573 patients with diabetes…  
  • Every additional dollar spent on statin therapy for diabetes patients without cardiovascular disease has produced health gains valued between $7 and $31.  
  • Blood Pressure Control in Patients with Diabetes
    Tight blood pressure control in type 2 diabetes patients reduced progression of DR by 34% and risk of deterioration by 47% after 9 years.  
  • Remote Interpretation of Retinal Imaging for DR
    Use of remote interpretation of retinal imaging in diabetics sent via tele-ophthalmology, improved the frequency of screening from 32% to 71% in only 12 months.  
  • For diabetes patients aged 55 and older, medical nutrition therapy was found to reduce the use of hospital services by 9.5% and physicians services by 23.5%.